{"id":754300,"date":"2023-05-03T09:17:05","date_gmt":"2023-05-03T13:17:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/"},"modified":"2023-05-03T09:17:05","modified_gmt":"2023-05-03T13:17:05","slug":"neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/","title":{"rendered":"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting"},"content":{"rendered":"<h2>\nData highlights the Company\u2019s commitment to advancing TMS and improving patient outcomes<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>MALVERN, Pa., May  03, 2023  (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the Clinical TMS Society Annual Meeting in Colorado Springs, CO on May 4th \u2013 6th. Neuronetics will be a Gold Sponsor of the conference and will present data from NeuroStar\u2019s Outcomes Registry.\u00a0<\/p>\n<p>\u201cWe are pleased to support the Clinical TMS Society Annual Meeting, connect with TMS providers and researchers, and share our latest data,\u201d said Keith J. Sullivan, President and CEO of Neuronetics. \u201cWe take great pride in being the category leader in the space, and through our ongoing research, NeuroStar is helping inform and advance clinical best practices.\u201d<\/p>\n<p>On May 5, NeuroStar data from over 7,000 TrakStar\u00ae patients will be featured by industry leading TMS experts in a theater session and two scientific posters showcasing results from the NeuroStar Outcomes Registry, the world\u2019s largest registry of clinical outcomes in major depressive disorder (MDD):<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Theater Session: Latest Data from NeuroStar\u2019s Clinical Outcomes Registry Evidence for TMS Effectiveness with Complete Treatment, Extended Treatment, and Re-treatment<\/strong>\u00a0&#8211; Dr. Scott Aaronson, Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt, will review data analyzing the relationship between treatments completed and clinical outcome using NeuroStar TMS in MDD.<\/li>\n<li>\n          <strong>Poster Abstract 19: To Taper or Not to Taper: That is the Question<\/strong>\u00a0&#8211; Dr. Kenneth Pages, Medical Director at TMS of South Tampa, will present data on the prevalence and impact of tapering TMS treatment at the end of the acute course.<\/li>\n<li>\n          <strong>Poster Abstract 35: TMS Again and Again: Re-treatment of Patients with MDD after an Acute Phase<\/strong><br \/>\n          <em>\u00a0<\/em><br \/>\n          <strong>Course<\/strong><br \/>\n          <em>\u00a0&#8211;\u00a0<\/em>Dr. Todd Hutton, Chief Medical Director of Southern California TMS Center, will present data on the frequency, timing, and clinical effectiveness of re-treatment with NeuroStar TMS.<\/li>\n<\/ul>\n<p>The NeuroStar Outcomes Registry leverages the Company\u2019s proprietary TrakStar data management system to make automated, large-scale, HIPAA-compliant data collection possible, contributing to research to improve clinical best practices.\u00a0\u00a0 For more information about NeuroStar, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GwVhwsigHmqSVjtqRfWGgFBLa99uJspvdfRV9i-MCiKTzaVxzkDjbuVmgwFObKeIl5cVgMgxEBRVQw0XU9NruQ==\" rel=\"nofollow noopener\" target=\"_blank\">neurostar.com<\/a>.<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong>Neuronetics<\/strong><br \/>\n        <br \/>Neuronetics, Inc.\u00a0believes that mental health is as important as physical health. As a global leader in neuroscience,\u00a0Neuronetics\u00a0is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn\u2019t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5.3 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world\u2019s largest depression Outcomes Registry.\u00a0Neuronetics\u00a0is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information,\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lJ28ai_qwDTcVCiuf1jLJc_UQTzNpCUmXYjLyQ51236QNymEM0ZqCnUfYZOklkMElhgaqKBSqAPsvrp3spmaBg==\" rel=\"nofollow noopener\" target=\"_blank\">www.neurostar.com<\/a><\/strong>.<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>EvolveMKD<br \/>646.517.4220<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r7L4Ytx8iRY8NlDl5hnzUzEyBHBgE3Hatwze1yGd7uG_zZpyJabzYvFXJbkQk8DJsqt2jjwveHXSRUfvlxwtcDe6D8VRkNOHVh8KaEU38nM=\" rel=\"nofollow noopener\" target=\"_blank\">NeuroStar@evolvemkd.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGQ5YWIxZjgtNWNlNi00OGFjLWIxNWMtNWFlYzQ4YmEyOWU2LTExMjIwMTE=\/tiny\/Neuronetics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data highlights the Company\u2019s commitment to advancing TMS and improving patient outcomes MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the Clinical TMS Society Annual Meeting in Colorado Springs, CO on May 4th \u2013 6th. Neuronetics will be a Gold Sponsor of the conference and will present data from NeuroStar\u2019s Outcomes Registry.\u00a0 \u201cWe are pleased to support the Clinical TMS Society Annual Meeting, connect with TMS providers and researchers, and share our latest data,\u201d said Keith J. Sullivan, President and CEO of Neuronetics. \u201cWe take &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754300","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data highlights the Company\u2019s commitment to advancing TMS and improving patient outcomes MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the Clinical TMS Society Annual Meeting in Colorado Springs, CO on May 4th \u2013 6th. Neuronetics will be a Gold Sponsor of the conference and will present data from NeuroStar\u2019s Outcomes Registry.\u00a0 \u201cWe are pleased to support the Clinical TMS Society Annual Meeting, connect with TMS providers and researchers, and share our latest data,\u201d said Keith J. Sullivan, President and CEO of Neuronetics. \u201cWe take &hellip; Continue reading &quot;Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-03T13:17:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting\",\"datePublished\":\"2023-05-03T13:17:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/\"},\"wordCount\":544,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/\",\"name\":\"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=\",\"datePublished\":\"2023-05-03T13:17:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting - Market Newsdesk","og_description":"Data highlights the Company\u2019s commitment to advancing TMS and improving patient outcomes MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the Clinical TMS Society Annual Meeting in Colorado Springs, CO on May 4th \u2013 6th. Neuronetics will be a Gold Sponsor of the conference and will present data from NeuroStar\u2019s Outcomes Registry.\u00a0 \u201cWe are pleased to support the Clinical TMS Society Annual Meeting, connect with TMS providers and researchers, and share our latest data,\u201d said Keith J. Sullivan, President and CEO of Neuronetics. \u201cWe take &hellip; Continue reading \"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-03T13:17:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting","datePublished":"2023-05-03T13:17:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/"},"wordCount":544,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/","name":"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=","datePublished":"2023-05-03T13:17:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ2MCM1NTYyNTE5IzIxMTA0NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-showcases-new-neurostar-tms-findings-at-clinical-tms-society-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neuronetics Showcases New NeuroStar\u00ae TMS Findings at Clinical TMS Society Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754300"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754300\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}